06127 JOINN
- 8.310
- -1.580-15.98%
JOINN News
Nomura Adjusts Joinn Laboratories' Price Target to HK$10.41 From HK$12.60, Keeps at Neutral
05:40 AM EDT, 04/30/2024 (MT Newswires) -- Nomura Adjusts Joinn Laboratories' Price Target to HK$10.41 From HK$12.60, Keeps at Neutral Price (HKD): $8.31, Change: $-1.58, Percent Change: -15.98%
Changes in Hong Kong stocks | Zhaoyan Pharmaceutical (06127) fell by more than 11%, and the impact of experimental impairment increased the company's year-on-year change from profit to loss in the first quarter
Zhaoyan Pharmaceutical (06127) fell by more than 11%. As of press release, it was down 11.12% to HK$8.79, with a turnover of HK$14.2872 million.
Selected announcements | BYD's net profit for the first quarter increased by nearly 11% year-on-year; CNPC's profit for the first quarter exceeded 45 billion yuan
ICBC's first quarter revenue fell nearly 3% year on year; Vanke Enterprise's first quarter revenue fell by more than 10% year on year.
Zhaoyan Pharmaceutical (06127) lost 272 million yuan to mother in the first quarter
According to the Zhitong Finance App, Zhaoyan Pharmaceutical (06127) released its report for the first quarter of 2024. Operating revenue was 325 million yuan (RMB, same below), down 12.07% year on year; net loss attributable to shareholders of listed companies was 272 million yuan, profit of 188 million yuan for the same period last year; basic loss per share was 0.36 yuan.
昭衍新藥：2024年度第一季度報告
昭衍新藥：2023年度報告
Hong Kong pharmaceutical stocks strengthened in the afternoon. Pharmaceutical Condra rose more than 5%, Pharmaceutical Biotech rose more than 4%, and Tiger Pharmaceuticals and Zhaoyan Pharmaceutical followed suit.
Hong Kong pharmaceutical stocks strengthened in the afternoon. Pharmaceutical Condra rose more than 5%, Pharmaceutical Biotech rose more than 4%, and Tiger Pharmaceuticals and Zhaoyan Pharmaceutical followed suit.
Zhaoyan New Pharmaceutical (06127): Wuxi Jinyifu New Biomedical Venture Capital Partnership (Limited Partnership) adds limited partner Xiangtang Heyi
Zhaoyan New Pharmaceutical (06127) was announced. On February 5, 2024, the board of directors reviewed and approved the “About...
昭衍新藥：董事會召開日期
Changes in Hong Kong stocks | Zhaoyan Pharmaceutical (06127.HK) fell more than 6%, leading the CRO concept, the possibility that the Federal Reserve will raise interest rates is still possible, and domestic innovative drugs are still in the adjustment cyc
CRO concept stocks continued to decline. As of press release, Zhaoyan Pharmaceutical (06127.HK) fell 5.98% to HK$9.28; Tiger Pharmaceuticals (03347.HK) fell 5.93% to HK$30.15; Kanglong Chemical (03759.HK) fell 5.18% to HK$8.78; and Pharmaceuticals (02359.HK) fell 3.96% to HK$32.75.
Guoxin Securities released a research report on April 15 stating that it gave Zhaoyan New Pharmaceutical (603127.SH) a purchase rating. The main reasons for the rating include: 1) revenue is basically flat throughout the year, and the profit side is under
Guoxin Securities released a research report on April 15 stating that it gave Zhaoyan New Pharmaceutical (603127.SH) a purchase rating. The main reasons for the rating include: 1) revenue is basically flat throughout the year, and the profit side is under pressure in the short term; 2) the company continues to promote an integrated layout to enhance core business capabilities; 3) the number of projects in the segment continues to grow, and the market share maintains an advantage; 4) there are plenty of orders in hand, and the expansion of production capacity and personnel ensures order execution. (Mainichi Keizai Shimbun)
Zhaoyan New Pharmaceutical (603127): Revenue was basically flat for the full year of 2023, and the results of the internationalization strategy showed results
Revenue remained flat throughout the year, and the profit side was under pressure in the short term. Revenue for the full year of 2023 was $2,376 million (+4.78%), net profit attributable to mother of $397 million (-63.04%), net profit not attributable to mother of $338 million
Bank Rating | Lyon: Upgraded Tiger Pharmaceuticals and Zhaoyan New Drug Ratings Benefit from Innovative Drug Support Policies
Glonghui, April 11 | Lyon published a research report saying that the mainland has continuously introduced policies on innovative drugs in recent weeks, and it has been seen that investors' confidence in innovative drug manufacturers has improved. In the mainland clinical research industry, the bank believes that Tiger Pharmaceuticals and Zhaoyan New Pharmaceuticals can benefit more from the government's new support policy than their peers. The bank raised Tiger Pharmaceuticals's rating from “outperforming the market” to “outperforming the market”. The target price was raised from HK$31.4 to HK$37.3 as the transparency of its earnings growth would improve from FY2025. The bank also upgraded the new drug rating to “outperform the market”, and the target price was raised from HK$9.8 to HK$11
Zhaoyan Pharmaceutical (603127) 2023 Annual Report Review: Profitability Under Short-term Pressure, Internationalization Continues to Advance
Guide to this report: Profitability is under pressure in the short term, capacity construction is increasing, internationalization continues to advance, optimistic about long-term growth space, and maintaining the rating of increasing holdings. Key investment points: Maintain an increase in holdings rating. 2023 revenue of $2,376 billion (+4.78%)
Changes in Hong Kong stocks | Most biomedical stocks rose, Cansino Biotech (06185.HK) rose more than 15% and issued support documents for innovative drugs
Biomedical stocks were mostly higher, with the CRO sector leading the way. As of press release, Cansino Biotech (06185.HK) rose 15.49% to HK$18.94; Junshi Biotech (01877.HK) rose 12.5% to HK$11.26; Zhaoyan Pharmaceutical (06127.HK) rose 9.58% to HK$9.72; Tiger Pharmaceuticals (03347.HK) rose 6.6% to HK$34.1; Pharmaceuticals (02268.HK) 6.3% to HK$19.92.
The Hong Kong stock CXO concept fluctuated and strengthened, and Zhaoyan Pharmaceutical rose more than 9%
The CXO concept of Hong Kong stocks fluctuated and strengthened. Zhaoyan Pharmaceutical rose more than 9%, Tiger Pharmaceuticals rose more than 6%, and Kanglong Chemical, Kingsley Biotech, and Pharmaceutical Kangde followed suit.
CRO concept stocks surged higher in the afternoon. Zhaoyan Pharmaceutical rose more than 8%, Tiger Pharmaceuticals rose more than 7%, and Norske, Haoyuan Pharmaceuticals, and Pharmaceutical Stone Technology rose more than 4%.
CRO concept stocks surged higher in the afternoon. Zhaoyan Pharmaceutical rose more than 8%, Tiger Pharmaceuticals rose more than 7%, and Norske, Haoyuan Pharmaceuticals, and Pharmaceutical Stone Technology rose more than 4%.
Zhaoyan New Pharmaceutical (603127): Profitability under short-term pressure, internationalization continues to advance
Guide to this report: Profitability is under pressure in the short term, capacity construction is increasing, internationalization continues to advance, optimistic about long-term growth space, and maintaining the rating of increasing holdings. Key investment points: Maintain an increase in holdings rating. 2023 revenue of $2,376 billion (+4.78)
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Beijing has brought great benefits to innovative drugs!
In the middle of the night of April 7, the Beijing Municipal Medical Security Administration suddenly issued a “Notice on Public Consultation on the “Certain Measures to Support the High-Quality Development of Innovative Medicines by 9 Departments Including the Beijing Municipal Medical Security Administration (2024) (Draft for Comments)”. The public submission period for this consultation draft is only 3 working days. The first section of the clinical study clearly proposed reducing the overall time required to start a clinical trial to 28 weeks.
Analysis
Price Target
No Data
